The Role of Wild-Type RAS in Oncogenic RAS Transformation

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• RAS oncogenes (HRAS, NRAS, KRAS) are frequently mutated in cancers.
• Wild-type (WT) RAS proteins influence signaling and drug resistance in RAS-mutated cancers.
• WT RAS proteins have complex, context-dependent roles, with some acting as tumor suppressors and others as tumor promoters.

Purpose of the Study:

• To investigate the multifaceted roles of WT RAS proteins in RAS-mutated cancers.
• To understand how WT RAS signaling contributes to tumor progression and therapeutic resistance.
• To identify potential therapeutic targets within the upstream signaling pathways of WT RAS.

Main Methods:

• Analysis of RAS family oncogenes and their WT counterparts.
• Investigation of RTK-dependent activation of WT RAS signaling.
• Evaluation of the role of WT RAS in proliferation and transformation.
• Identification of upstream signaling molecules (SHP2, SOS1, SOS2) as potential targets.

Main Results:

• WT RAS proteins exhibit opposing functions: the WT allele of the mutated RAS isoform can be tumor-suppressive, while WT RAS from non-mutated isoforms can be tumor-promoting.
• RTK-dependent activation of non-mutated WT RAS proteins drives tumor growth.
• Rebound activation of RTK-WT RAS signaling contributes to resistance against targeted therapies.
• WT RAS signaling is crucial for proliferation and transformation in RAS-mutated cancer cells.

Conclusions:

• WT RAS proteins are critical modulators of cancer cell behavior and therapeutic response.
• Targeting upstream regulators like SHP2, SOS1, and SOS2 is a promising strategy for treating RAS-mutated cancers.
• Understanding the complex roles of WT RAS is essential for developing effective cancer therapies.